China Universal Asset Management Co. Ltd. Acquires 33,206 Shares of Royalty Pharma plc (NASDAQ:RPRX)

China Universal Asset Management Co. Ltd. raised its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 62.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 86,190 shares of the biopharmaceutical company's stock after buying an additional 33,206 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Royalty Pharma were worth $2,438,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Inspire Investing LLC boosted its position in Royalty Pharma by 175.1% during the first quarter. Inspire Investing LLC now owns 43,524 shares of the biopharmaceutical company's stock valued at $1,322,000 after purchasing an additional 27,701 shares during the last quarter. New Century Financial Group LLC bought a new stake in Royalty Pharma in the first quarter worth approximately $1,091,000. Swedbank AB increased its stake in shares of Royalty Pharma by 30.6% during the 2nd quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company's stock worth $285,151,000 after purchasing an additional 2,533,570 shares during the last quarter. Canada Pension Plan Investment Board raised its holdings in Royalty Pharma by 5.2% during the first quarter. Canada Pension Plan Investment Board now owns 923,639 shares of the biopharmaceutical company's stock valued at $28,051,000 after buying an additional 45,839 shares in the last quarter. Finally, Tidal Investments LLC lifted its holdings in Royalty Pharma by 28.2% in the 1st quarter. Tidal Investments LLC now owns 90,149 shares of the biopharmaceutical company's stock worth $2,740,000 after purchasing an additional 19,834 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Price Performance

Shares of RPRX stock traded down $0.11 during trading hours on Tuesday, hitting $27.15. The company had a trading volume of 1,832,238 shares, compared to its average volume of 2,578,422. The firm has a market capitalization of $16.22 billion, a price-to-earnings ratio of 20.34, a PEG ratio of 3.97 and a beta of 0.46. The firm's fifty day moving average is $28.02 and its 200 day moving average is $27.59. Royalty Pharma plc has a 12 month low of $25.20 and a 12 month high of $31.66. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The firm had revenue of $537.00 million for the quarter, compared to analysts' expectations of $600.83 million. During the same period last year, the firm earned $0.85 earnings per share. On average, sell-side analysts predict that Royalty Pharma plc will post 4.05 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date is Friday, November 15th. Royalty Pharma's dividend payout ratio is presently 62.69%.

Analyst Ratings Changes

A number of research firms have recently commented on RPRX. StockNews.com lowered shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Monday. Citigroup decreased their target price on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating for the company in a research note on Friday. The Goldman Sachs Group raised their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a "buy" rating in a research report on Wednesday, August 14th. Finally, Morgan Stanley increased their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $41.67.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.